Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670017 · ClinicalTrials.gov registry record · NA
Glucose Time-In-Range Development Evaluation
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 68
- Enrollment target
NCT03670017 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 68 participants.
The verdict
NCT03670017, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
Study Summary
The study will evaluate patients requiring frequent glucose monitoring in a Surgical ICU. The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
Interventions
- DEVICE OptiScanner® 5000 Glucose Monitoring System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2020-09-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670017
The ClinicalTrials.gov registry entry for NCT03670017 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OptiScanner® 5000 Glucose Monitoring System is the first listed.
NCT03670017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03670017 about?
NCT03670017 is a clinical study titled "Glucose Time-In-Range Development Evaluation". The study will evaluate patients requiring frequent glucose monitoring in a Surgical ICU. The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Cathete...
What is the current status of trial NCT03670017?
This trial is currently terminated. It is a NA study. The enrollment target is 68 participants. The study started on 2018-09-06. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03670017?
The interventions under investigation include: OptiScanner® 5000 Glucose Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT03670017?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.